Compare PNTG & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PNTG | TNDM |
|---|---|---|
| Founded | 2019 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.4B |
| IPO Year | 2019 | 2013 |
| Metric | PNTG | TNDM |
|---|---|---|
| Price | $31.46 | $25.14 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 18 |
| Target Price | ★ $36.60 | $28.33 |
| AVG Volume (30 Days) | 281.0K | ★ 2.4M |
| Earning Date | 05-05-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.00 | N/A |
| EPS | ★ 0.84 | N/A |
| Revenue | $947,705,000.00 | ★ $1,014,736,000.00 |
| Revenue This Year | $24.93 | $8.01 |
| Revenue Next Year | $7.52 | $12.14 |
| P/E Ratio | $36.82 | ★ N/A |
| Revenue Growth | ★ 36.31 | 7.93 |
| 52 Week Low | $21.74 | $10.00 |
| 52 Week High | $35.25 | $29.65 |
| Indicator | PNTG | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 45.30 | 62.02 |
| Support Level | $26.89 | $19.66 |
| Resistance Level | $31.94 | $29.65 |
| Average True Range (ATR) | 1.33 | 1.21 |
| MACD | -0.42 | 0.20 |
| Stochastic Oscillator | 20.12 | 79.95 |
Pennant Group Inc is engaged in providing healthcare services to patients of all ages, including the growing senior population, in the United States. It operates in multiple lines of business including home health, hospice, and senior living which includes the company's assisted living, independent living, and memory care communities across Arizona, California, Colorado, Idaho, Montana, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin, and Wyoming. It operates in two segments; home health and hospice services and senior living services. The company generates majority of its revenue from home health and hospice services segment, which includes its home health, hospice and home care businesses.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.